Therapeutic combinations and compositions for the treatment of inflammatory bowel disease (II)Dijkstra, G., Faber, K. N., Harmsen, H. J. M., Steinert, R., Sybesma, W. & Topchyan, A., 13-Aug-2020, Patent No. WO2020161089, 4-Feb-2020, Priority date 4-Feb-2019
Research output: Patent
The present invention relates to pharmaceutical combinations of at least one TNF inhibitor and riboflavin to treat patients suffering from inflammatory bowel disease (IBD) or other inflammatory conditions (such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, lupus erythematous and multiple sclerosis). This invention also relates to additive and/or combinations of at least one TNF inhibitor and riboflavin. This invention is also related to a method for the treatment or prophylaxis of IBD, which method comprises administering a therapeutically effective amount of TNF inhibitor and riboflavin.
|Publication status||Published - 13-Aug-2020|